Bathi resik saben saham (EPS TTM): Sonoma Pharma (SNOA)

Aggressive marketing to maintain market positions is stimulating demand, and the rolling annual earnings per share for Sonoma Pharmaceuticals (SNOA) on GURU.Markets reflects this momentum, with the current figure standing at -0.91. Growth is driven by innovations in acne treatment and veterinary medicine, while operational resilience is ensured by the company's own manufacturing plant in Mexico producing chlorhexidine solutions.
Rincian analitis lan laporan data perusahaan Sonoma Pharmaceuticals (SNOA)

Earnings per share (EPS) measures the portion of equity allocated to each security over a year. For Sonoma Pharmaceuticals (SNOA), this metric reflects the monetization efficiency of expanding into antiseptic and veterinary product markets. Analyzing the trailing 12-month earnings per share allows for an assessment of the business's actual profitability. Steady growth in this metric confirms resilient demand across pharmacy chains, while a downward trend signals risks of asset impairment.